A pharmaceutical compositionfor treatment of persons afflicted ofheart failure with preserved ejection fraction(HFPEF), diastolic heart failure(DHF) or diastolic dysfunction (DF), thecomposition comprising a therapeuticallyeffective amount of a compound capable ofspecific binding to the relaxin receptor(RXFPI) present on fibroblasts, fibromyoblasts,endothelial cells, eudocardial cells,and cardiomyoeytes in the cardiac muscleto increase the heart's stroke volume atlower end-diastolic pressure.
